Abstract

ObjectiveUveitis and retinal vasculitis are sight-threatening manifestations of Behçet's disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab),...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With Brolucizumab.
Hana Yoshida ... Yuto Hashimoto
Investigative ophthalmology & visual science | VOL. 65
Hana Yoshida, et. al.Hana Yoshida ... Yuto Hashimoto
03 Jan 2024
Ocular tuberculosis: diagnostic and treatment challenges
William Hodge ... Gonzalo G Alvarez
International Journal of Infectious Diseases | VOL. 13
William Hodge, et. al.William Hodge ... Gonzalo G Alvarez
22 Apr 2009
Multimodal Imaging of Parry Romberg Syndrome-associated Panuveitis: A Case Report and Review of Literature
Jialiang Duan ... Nalei Zhou
Ocular Immunology and Inflammation | VOL. 29
Jialiang Duan, et. al.Jialiang Duan ... Nalei Zhou
02 Oct 2019
P27 A case of unilateral scleritis and biopsy proven retinal vasculitis in an elderly woman with rheumatoid arthritis and previous retinal detachment surgery with silicone oil band
John Downie ... Stephanie Young
Rheumatology Advances in Practice | VOL. 7
John Downie, et. al.John Downie ... Stephanie Young
27 Sep 2023
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers